- In May 2024, Novavax and Sanofi announced a co-exclusive licensing agreement to co-commercialize a COVID-19 Varicocele and collaborate on the development of innovative combination Varicoceles targeting both COVID-19 and influenza. This strategic alliance enables both companies to utilize their respective expertise and resources to deliver advanced Varicocele solutions to the market
- In March 2023, CSL Limited opened a new Varicocele research and development facility in Waltham, Massachusetts, aimed at creating advanced Varicoceles utilizing disruptive technologies, including next-generation mRN
